アブストラクト
| Title | SGLT2阻害薬 - 心不全の立場から |
|---|---|
| Subtitle | 特集 心腎連関から新薬まで! 心×腎疾患の薬物治療 心腎領域の新薬 |
| Authors | 矢崎麻由 |
| Authors (kana) | |
| Organization | 北里大学病院循環器内科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 4 |
| Page | 738-741 |
| Year/Month | 2022 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points]●SGLT2阻害薬は近位尿細管での尿中グルコースの再吸収を阻害し, 尿中に排出する薬剤である. ●SGLT2阻害薬は血糖降下作用だけでなく, 血圧低下, 尿量増加, 体重減少などさまざまな効果があることが知られている. ●慢性心不全患者へのSGLT2阻害薬投与は, 糖尿病の有無にかかわらず, 心血管アウトカムを改善させた. ●SGLT2阻害薬は慢性心不全患者の標準治療薬の一つとして位置づけられるようになった. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Inzucchi SE, et al : SGLT-2 inhibitors and cardiovascular risk : proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res, 12 : 90-100, 2015
- 2) Zinman B, et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 373 : 2117-2128, 2015
- 3) Neal B, et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 377 : 644-657, 2017
- 4) Wiviott SD, et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 380 : 347-357, 2019
- 5) McMurray JJV, et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 381 : 1995-2008, 2019
残りの16件を表示する
- 6) Packer M, et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med, 383 : 1413-1424, 2020
- 7) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療(https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf)
- 8) Vaduganathan M, et al : Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction : a comparative analysis of three randomised controlled trials. Lancet, 396 : 121-128, 2020
- 9) Eshaghian S, et al : Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol, 97 : 1759-1764, 2006
- 10) Konstam MA, et al : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA, 297 : 1319-1331, 2007
- 11) Cleland JGF, et al : The perindopril in elderly people with chronic heart failure(PEP-CHF) study. Eur Heart J, 27 : 2338-2345, 2006
- 12) Yusuf S, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet, 362 : 777-781, 2003
- 13) Yamamoto K, et al : Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study(J-DHF). Eur J Heart Fail, 15 : 110-118, 2013
- 14) Pitt B, et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 370 : 1383-1392, 2014
- 15) Anker SD, et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med, 385 : 1451-1461, 2021
- 16) Solomon SD, et al : Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction : rationale and design of the DELIVER trial. Eur J Heart Fail, 23 : 1217-1225, 2021
- 17) Wojcik C, et al : Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors. Curr Cardiol Rep, 21 : 130, 2019
- 18) Ronco C, et al : Cardiorenal syndrome. J Am Coll Cardiol, 52 : 1527-1539, 2008
- 19) Verma S, et al : SGLT2 inhibitors and mechanisms of cardio-vascular benefit : a state-of-the-art review. Diabetologia, 61 : 2108-2117, 2018
- 20) Heerspink HJL, et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med, 383 : 1436-1446, 2020
- 21) Herrington WG, et al : The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease : a rationale for the EMPA-KIDNEY study. Clin Kidney J, 11 : 749-761, 2018
